Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2009. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to disclosure of director share allocations and does not contain financial performance data.
Material Changes
On September 30, 2009, the Company's Non-Executive Directors were provisionally allocated awards over Ordinary shares and American Depository Shares (ADSs) for the service period of July 1, 2009, to September 30, 2009. The allocation price was set at £12.41 per Ordinary share and $39.60 per ADS. The specific allocations were:
- Sir Christopher Gent: 2,719.58 Ordinary Shares
- Prof. Sir Roy Anderson: 528.810 ADSs
- Dr Stephanie Burns: 330.08 ADSs
- Mr Lawrence Culp: 330.08 ADSs
- Sir Crispin Davis: 1,913.78 Ordinary Shares
- Sir Deryck Maughan: 330.080 ADSs
- Mr James Murdoch: 377.72 ADSs
- Dr Daniel Podolsky: 424.39 ADSs
- Mr Tom de Swaan: 528.81 ADSs
- Sir Robert Wilson: 528.81 ADSs
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) regarding director transactions.
Investor Verification Points
- Verify the final vesting status of the provisional share allocations listed for Non-Executive Directors.
- Confirm the exchange rate used to convert the £12.41 Ordinary share price to the $39.60 ADS price.
- Review the full share allocation arrangements for Non-Executive Directors to understand the terms of service and eligibility.